FIELD: medicine.
SUBSTANCE: group of inventions refers to cancer immunotherapy, particularly pancreatic duct adenocarcinoma (PDAC). What is presented are agents and methods of treating a population of patients suffering PDAC tumors expressing a wild-type KRAS protein. Embodiments of the invention include administering nimotuzumab to a patient with PDAC expressing a wild-type KRAS having a sequence, corresponding to SEQ ID NO: 7 or SEQ ID NO: 24, and does not contain a mutation in amino acid residue of codon G12. Method may involve addition of other anticancer agents. Also disclosed is a method of predicting the immunity of a patient suffering PDAC, to treating with nimotuzumab based on the presence of a KRAS mutation in the tumor; wherein the presence of a KRAS mutation in the amino acid residue of the G12 codon of SEQ ID NO: 7 or SEQ ID NO: 24 indicates that said patient will be non-responsive to nimotuzumab treatment.
EFFECT: group of inventions enables increasing the survival rate of PDAC patients.
23 cl, 4 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY | 2013 |
|
RU2677245C2 |
| PEPTIDE VACCINE COMPRISING RAS PEPTIDE CONTAINING MUTATIONS, AND CHEMOTHERAPEUTIC AGENT | 2015 |
|
RU2700929C2 |
| METHODS AND SETS RELATED TO CAPTURE OF CA-IX-POSITIVE EXOSOMES | 2018 |
|
RU2770592C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN TREATMENT OF NRAS MUTATED CANCER | 2015 |
|
RU2683276C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| SPECIFIC BINDING PROTEINS AND APPLICATIONS THEREOF | 2010 |
|
RU2549678C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| SPECIFIC BINDING PROTEINS AND APPLICATIONS THEREOF | 2010 |
|
RU2673724C2 |
